MCM2 and cancer: Secondly, given that MCM2 is highly expressed in several types of cancers (including PDAC), and that MCM2 has a much longer half-life as compared to other proliferation markers (e.g. Ki-67), it might take more time before the inhibitory effects of UAMC-2526 on MCM2 expression are visible.